Alkermes (ALKS) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-45.54M
Depreciation	8.65M
Share-based compensation expense	19.83M
Other non-cash charges	1.86M
Receivables	2.35M
Inventory, prepaid expenses and other assets	5.21M
Accounts payable and accrued expenses	6.95M
Deferred revenue	635K
Other long-term liabilities	-88K
Payment of non-recourse RISPERDAL CONSTA secured 7% notes principal attributable to original issue discount	-6.61M
Cash flows used in operating activities	-5.91M
Purchase of property, plant and equipment	-9.4M
Sales of property, plant and equipment	395K
Purchases of investments	-370.38M
Sales and maturities of investments	385.51M
Cash flows provided by investing activities	5.63M
Proceeds from the issuance of common stock for share-based compensation arrangements	4.74M
Payment of non-recourse RISPERDAL CONSTA secured 7% notes principal
Cash flows provided by (used in) financing activities	-40.65M
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-40.93M
CASH AND CASH EQUIVALENTS - Beginning of period	79.32M
CASH AND CASH EQUIVALENTS - End of period	38.39M
Cash paid for interest	1.68M
Cash paid for taxes	60K
Purchased capital expenditures included in accounts payable and accrued expenses

Entities mentioned with ALKS

View All Entities